Celanese in drug delivery research pact with Johns Hopkins

Celanese announced an agreement with Johns Hopkins University Department of Ophthalmology to collaborate on a study of sustained drug delivery to the suprachoroidal space in the eye. Direct administration of therapeutics to the suprachoroidal space is growing more common as an approach for the treatment of retinal disorders. Treatment currently consists of frequent ocular injections performed at the physician’s office. A bioinert implant based on the VitalDose platform can provide sustained ocular drug delivery for greater than six months, providing an alternative approach for reliable, continuous dosing and reducing the treatment burden for the patient. The VitalDose Drug Delivery Platform independently has proven biocompatibility and achieves greater than six months release of mAbs, peptides, small molecules and RNAi therapeutics, making it suitable for delivering a variety of therapeutics used for ophthalmologic conditions